Table 1. Elimination of mixed allogeneic... | American Society of Hematology

Table 1.

Elimination of mixed allogeneic chimerism in stable chimeras by anti-RT7^a monoclonal antibody treatment

Day	Chimerism, %			Lineage	Treatment
Day	No. 1	No. 2	No. 3	Lineage	Treatment
0	0	0	0		LEW.7B + LEW.1A BMT
27	15	15	30	Multilineage
62	15	15	30	Multilineage
63					Anti-RT7^amAb
66					Anti-RT7^a mAb
70					Anti-RT7^a mAb
97	7	5	5	Mainly B cells
105	6	4	4	Mainly B cells
122					Anti-RT7^a mAb
134	7	6	7	Mainly B cells
204	7	3	4	Mainly B cells
223	3	2	4	Mainly B cells
520	< .5		< .5	Few donor cells left

Day	Chimerism, %			Lineage	Treatment
Day	No. 1	No. 2	No. 3	Lineage	Treatment
0	0	0	0		LEW.7B + LEW.1A BMT
27	15	15	30	Multilineage
62	15	15	30	Multilineage
63					Anti-RT7^amAb
66					Anti-RT7^a mAb
70					Anti-RT7^a mAb
97	7	5	5	Mainly B cells
105	6	4	4	Mainly B cells
122					Anti-RT7^a mAb
134	7	6	7	Mainly B cells
204	7	3	4	Mainly B cells
223	3	2	4	Mainly B cells
520	< .5		< .5	Few donor cells left

LEW.1A rats (n = 3) were treated with 11 Gy of total body irradiation on day −1 and received 100 × 10⁶ bone marrow cells of LEW.7B and LEW.1A native donors (50% each) on day 0. High doses of anti-RT7^a monoclonal antibody (mAb) (Figure4) were injected on days 63, 66, 70, and 122. Leukocyte chimerism was analyzed in peripheral blood samples by flow cytometry after staining with lineage-specific mAbs (Figure 1, indirect staining) and anti-RT7^a mAb (direct staining).

BMT indicates bone marrow transplantation; mAb, monoclonal antibody.

View Large